$0.9800
-0.04-3.92%
At close: Nov 11, 4:00 PM EST
$0.9629
-0.0571-5.6%
Pre-Market: 8:18 AM EST
PDS Biotechnology Corp
PDSBNASDAQ
PDS Biotechnology rose 20.7% from $0.85 to $1.02, ahead of the S&P 500's +12.7%. Its worst day was Aug 11 (−64.9%), and its low came Aug 19 at $0.20.
Nov 13, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.19 beat the $-0.20 estimate on $0.00 revenue.
0.0% · S&P 500 −1.7%
EPS of $-0.14 beat the $-0.20 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
−0.9% · S&P 500 −0.3%
78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35%Trials performed in
+28.3% · S&P 500 +0.8%
EPS of $-0.13 beat the $-0.14 estimate on $0.00 revenue.
+20.9% · S&P 500 +0.6%
EPS of $-0.18 missed the $-0.13 estimate on $0.00 revenue.
−3.6% · S&P 500 +0.7%
PDS Biotechnology shares rose 36.4%, while the S&P 500 fell 0.5%.
+36.4%, on 491M shares, the year's heaviest volume · S&P 500 −0.5%
PDS Biotechnology shares rose 69.2%, while the S&P 500 fell 0.4%.
+69.2%, the year's best day · S&P 500 −0.4%
PDS Biotechnology shares rose 60.3%, while the S&P 500 rose 0.7%.
+60.3% · S&P 500 +0.7%
PDS Biotechnology closed at its highest level of the year, 89.3% above where the year started.
+5.3% · S&P 500 0.0%
PDS Biotechnology shares rose 29.1%, while the S&P 500 rose 0.5%.
+29.1% · S&P 500 +0.5%
Where it ended: a close of $1.02 on Nov 11, 2026. Up next: Q3 2026 earnings on Nov 13, 2026 (EPS est. $-0.09).
Nothing in the past 12 months.
All PDSB dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for PDSB and SPY from Benzinga historical bars. Not investment advice.
